S. Raby

Cancer Immunotherapy Trials Underutilize Immune Response Monitoring

D. Fearon, D. Jodrell, T. Janowitz, 2017, The Oncologist.

Utility of Prognostic Markers in Second-line Treatment of Metastatic Urothelial Cancer.

T. Elliott, J. Weaver, R. Conroy, 2017, Clinical oncology (Royal College of Radiologists (Great Britain)).

An unexpected finding after a fall from a horse

B. Huntly, S. Raby, D. Greaves, 2013, BMJ : British Medical Journal.

The role of palliative radiotherapy in bladder cancer: a narrative review.

P. Hoskin, A. Choudhury, S. Raby, 2020, Annals of palliative medicine.

Cancer immunotherapy trial registrations increase exponentially but chronic immunosuppressive glucocorticoid therapy may compromise outcomes

D. Fearon, D. Jodrell, T. Janowitz, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Reprogramming the immunosuppressive tumor microenvironment results in successful clearance of tumors resistant to radiation therapy and anti-PD-1/PD-L1

I. Mills, T. Illidge, L. Zeef, 2023, Oncoimmunology.

Radiotherapy for High-grade T1 Bladder Cancer.

A. Choudhury, S. Raby, 2018, European urology focus.

The AGAMENON-SEOM model for prediction of survival in patients with advanced HER2-positive oesophagogastric adenocarcinoma receiving first-line trastuzumab-based therapy

O. Mirallas, V. Arrazubi, P. Jiménez-Fonseca, 2023, Therapeutic advances in medical oncology.

The Medical butterfly effect; how a discovery in a rare disease can have large effects elsewhere.

S. Raby, 2010 .